DDInter623 DDInter1147
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Efalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Efalizumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Efalizumab may lead to a major life threatening interaction when taken with Leflunomide